Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension

Consecutively hospitalized patients with confirmed coronavirus disease 2019 (COVID-19) in Wuhan, China were retrospectively enrolled from January 2020 to March 2020 to investigate the association between the use of renin–angiotensin system inhibitor (RAS-I) and the outcome of this disease. Associati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huai-yu, Peng, Suyuan, Ye, Zhanghui, Li, Pengfei, Li, Qing, Shi, Xuanyu, Zeng, Rui, Yao, Ying, He, Fan, Li, Junhua, Liu, Liu, Ge, Shuwang, Ke, Xianjun, Zhou, Zhibin, Xu, Gang, Zhao, Ming-hui, Wang, Haibo, Zhang, Luxia, Dong, Erdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267232/
https://www.ncbi.nlm.nih.gov/pubmed/34241787
http://dx.doi.org/10.1007/s11684-021-0850-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267232/
https://www.ncbi.nlm.nih.gov/pubmed/34241787
http://dx.doi.org/10.1007/s11684-021-0850-9

Ejemplares similares